

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/029039 A1

(51) International Patent Classification⁷: C07D 401/04

(74) Agents: SARMA, Krishna et al.; Corporate Law Group,
1106-1107 Kailash building, 26 K. G. Marg, New Delhi
110 001 (IN).

(21) International Application Number:
PCT/IN2002/000193

(22) International Filing Date:
24 September 2002 (24.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.

(71) Applicant (*for all designated States except US*):
MOREPEN LABORATORIES LIMITED [IN/IN];
505 Ansal Bhavan, 16 K. G. Marg, New Delhi 110 001
(IN).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SURI, Sanjay
[IN/IN]; Morepen Laboratories Limited, 505 Ansal Bha-
van 16 K. G. Marg, New Delhi 110 001 (IN). SINGH,
Jujhar [IN/IN]; Morepen Laboratories Limited, 505 Ansal
Bhavan 16 K. G. Marg, New Delhi 110 001 (IN). NAIM,
Syed, Shawkat [IN/IN]; Morepen Laboratories Limited,
505 Ansal Bhavan 16 K. G. Marg, New Delhi 110 001
(IN).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

WO 2004/029039 A1

(54) Title: AN IMPROVED PROCESS FOR THE PRODUCTION OF DESLORATADINE

(57) Abstract: An improved process for the production of Desloratadine is described wherein Loratadine is reacted with neat alcohol in presence of inorganic base, followed by isolating Desloratadine on addition of excess water in crystalline form.


AN IMPROVED PROCESS FOR THE PRODUCTION OF DESLORATADINE

BACKGROUND OF THE INVENTION

5. This invention relates to an improved process for the production of Desloratadine.

The present invention particularly provides a process for the production of Desloratadine (DCL) with high yield, high purity, and very low residual solvent. Desloratadine is known as descarboethoxyloratadine. Its chemical name is 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]cyclohepta[1,2-b]

10. pyridine and represented by the structural formula 1.



(I)

15. DCL is a metabolic derivative of loratadine, an H-1 histamine receptor antagonist.

Loratadine has been shown to be effective in treating numerous disorders, including, but not restricting to, colds, chronic urticaria, seasonal allergic rhinitis and seasonal perennial rhinitis. Due to its antihistaminic activity, it is found useful for the treatment of allergic asthma, diabetic retinopathy and other small vessel

20. disorders associated with

the diabetes mellitus. Though loratadine belongs to a class of non-sedative antihistamines, a strong potential exists for an adverse interaction between inhibitors of cytochrome P450 and loratadine. Hence, concurrent administration of loratadine with ketoconazole, itraconazole or antibiotic like erythromycin need to be done cautiously. DCL in addition to

being non-sedative antihistamine, also avoids many adverse side effects associated with loratadine. According to literature DCL is 2.5 to 4 times, more active orally than loratadine and antihistamine activity

5. tests for 24 hrs (Arzneim. Forsch./Drug Res. 50(1) Nr.4 (345-352)2000).

Importantly, it has been shown that DCL is 5 to 7 times less active in tumor promotion than loratadine and is at least 20 times more potent at histamine receptor when compared to loratadine. Hence it is more desirable to have DCL containing

10. pharmaceutical compositions. However, over time DCL with lactose produce a brown coloured product and there is a high degree of DCL degradation.

The Hungarian Patent Number 194864, describes following two methods for the preparation of desloratadine from Loratadine (chemical name: 8-chloro-6, 11-

15. dihydro-11-(1-ethoxy carbonyl-4-piperidylidene) -5H-benzo [5,6] cyclohepta[1,2-b] pyridine:

(a) the 8-chloro-6, 11-dihydro-11-(1-ethoxycarbonyl-4-piperidylidene) -5H-benzo [5,6] cyclohepta[1,2-b] pyridine (loratadine) is decarboxylated by boiling with aqueous ethanolic sodium hydroxide solution for 24 hrs, then isolating

20. DCL as acetate after neutralizing the solution with acetic acid. The crude product has to be further purified. The yield after recrystallization from benzene-hexane mixture amounts to 70%

(b) 8-chloro-6, 11-dihydro-11-(1-methyl-4-piperidylidene) -5H-benzo [5,6] cyclohepta[1,2-b] pyridine (azatadine) is demethylated in 2 steps: the 1-cyano

25. derivative is synthesized with cyanogen bromide and then hydrolysed with concentrated HCl in acetic acid for 20 hrs. The residue after evaporating solvent is neutralized with NH₄OH solution to get DCL.

The above processes have several disadvantages. During the realization of process substantial decomposition takes place leaving several impurities in the final

30. product. While purifying the product by recrystallisation, substantial material is lost. The base obtained is insoluble in water and poses problems in the preparation of formulation.

Process (b) is disadvantageous in itself, because of the use of poisonous cyanogen bromide reagent and the poisonous methyl bromide formed. It also had the

35. disadvantageous of the method (a).

The US Patent No. 4, 659, 716 also teaches preparation of DCL by dealkylation of azatadine by reaction with cyanogen bromide followed by acid hydrolysis and decarbethoxylation of loratadine by refluxing either with KOH and EtOH/Water (1:1) for 66 hrs or NaOH and 70% EtOH for 24 hrs with yield ranging from 90 to

5. 95%. The product obtained is coloured in addition to the disadvantages outlined above and thus needs further purification.

US Patent No. 4, 826, 853 exemplifies the preparation of DCL by cleaving ethoxy group of loratadine via acid (HCl) or base (KOH) hydrolysis. It also advises

10. treating it with organometallic reagent (CH_3Li) and a reductive agent (Zn in acid). DCL is also prepared by refluxing Loratadine with KOH in aqueous ethanol for 64 hrs. Recrystallisation can be carried out using toluene. The yield is 77%.

As per US Patent No. 5, 925, 648 and PCT No. WO98/11,092 and WO98/04545

15. (US.97/12923), DCL may be prepared by hydrolyzing loratadine as specified above wherein refluxing may be effected for about 60 hrs using EtOH and HCl in anhydrous state followed by basifying with KOH or NaOH and extracting with CH_2Cl_2 .

20. European Patent No. 0208855 also teaches the preparation of DCL by following methods:

- dealkylation of azatadine using cyanogen bromide followed by hydrolysis; and
 - refluxing Loratadine with KOH and aqueous ethanol for 66 hrs to
25. give 95% yield as acetate. A combination of EtOH/Water (1:1) and NaOH also has been exemplified.

PCT application No. WO 8503707 or European Patent No. 0152897 also teaches preparation of DCL either by demethylation through cyanogen route or through

30. decarbethoxylation by refluxing loratadine with EtOH and NaOH for 24 hrs resulting into crude coloured product as thick emulsion that can not be filtered or isolated easily. More over, since the product obtained is crude, requires further purification. 6.0 g of loratadine results in to 4.0 to 4.5 g of DCL European Patent application No. 93108177.2 [0577957A1 (ES2, 042, 421)] teaches preparation of DCL by treating loratadine with dry chloroform and trimethylsilyl iodide at 55 to 60°C overnight followed by treatment with

HCl and basifying with NaOH. Product needs extraction and further purification. The yield is 77%.

5 PCT application No. WO96/31478 proposes preparation of iodoamine through hydrolysis procedure prescribed in Example 358 step A of WO 95/10516 with 89% yield and preparation of bromoamine through again hydrolysis prescribed in Example 358 step A of WO 95/10516 with 69% yield. This procedure may be applicable to the preparation of DCL.

10 PCT application No. WO 95/10514 also teaches preparation of DCL via cyanogen route or alkali hydrolysis route. It exemplifies use of aqueous Ethanol and KOH giving 77% yield after reflux for 64 hrs.

15 US Patent No. 5, 595, 997 advocates saponification of loratadine using sodium hydroxide and absolute ethanol to produce DCL after reflux for 4 days as pale-tan solid. The derivative needs to be extracted with methylene chloride.

20 PCT application No. WO 95 10516 suggests preparation applicable to DCL via acid hydrolysis of loratadine using HCl followed by neutralizing with NaOH and extracting with CH_2Cl_2 .

25 PCT application No. WO 99/01450, basically teaching the preparation of DCL polymorphs 1 & 2 advises preparation of DCL polymorph 1 through reflux of loratadine with KOH flakes in industrial methylated spirit for 3 hrs followed by addition of water and crystallizing with MIBK.

Reference also can be made to PCT application No. WO / 03707, WO 92/00293, WO 95/10515 that describes the preparation of DCL.

30 It can be seen that the existing processes either relate to treating azatadine with cyanogen bromide followed by acid hydrolysis & neutralization or relate to alkali or acid hydrolysis of loratadine using alkali metal hydroxide with aqueous alcohol. The processes involve refluxing for a longer period ranging from 24 to 66 hrs or even more upto 4 days. The product is invariably coloured and needs further purification.

The yield varies from 77 to 90 %. The processes suffer from one or the other disadvantages as outlined above.

SUMMARY OF THE INVENTION

In our experiments, we have found out that the process of the present invention is unexpectedly advantageous for the commercial scale production of the title compound with high yield, high purity, and low value residual solvent. The process is more economic in addition to being eco-friendly. It has greatest degree of reproducibility.

Accordingly the main object of the present invention is to provide a process for the production of Desloratadine having structural formula 1 which obviates the draw backs of the existing processes.

Another object is to provide a process viable for the commercial production of the title compound.

Still another object of the present invention is to provide a process that can produce a compound, which meets GMP requirements, ICH requirements and health registration requirements Further the compound should be in pure form having consistent properties with minimum side effects and good stability.

Accordingly the present invention provides an improved process for the production of Desloratadine which comprises, reacting loratadine with neat alcohol in presence of inorganic base, and isolating the title compound in crystalline form by conventional methods on addition of excess water.

One of the embodiments of the present invention is that the alcohol used may be alkanols of 1 to 10 carbon atoms.

The alkanols of 1 to 10 carbon atoms used may be methanol, ethanol, propanol, isopropanol, tert. butyl alcohol, pentanol, hexanol, cycloalkanols such as cyclohexanol; aromatic alcohols such as benzyl alcohol.

How However, the scope of the present invention is not limited to the above mentioned alcohols, but can also be extended to other alcohols.

The alcohol used may preferably be a C₁-C₄ alkanol, more preferably methanol.

The another embodiment is that the amount of alcohol may vary between 1 and 10 w/v equivalents calculated on the starting compound- loratadine.

The amount of alcohol used may preferably be 2-6 equivalents, more preferably be 4 equivalents.

5 Yet another embodiment of the invention is that the inorganic base which may be used in the process of the invention are alkali metal hydroxide.

The alkali metal hydroxide used may be such as sodium hydroxide, potassium hydroxide

The preferred alkali metal hydroxide used, may be sodium hydroxide.

The amount of base used may vary between 0.5 and 1.6 w/w equivalents calculated on the starting compound – loratadine.

10 Preferably 1-1.6 equivalents of base may be used, more preferably 1.1 equivalents may be used.

The reaction may be carried out at a temperature between 60° and 100° C or at respective refluxing temperature, preferably between 80° and 95° C more preferably 85 to 90 °C.

15 The amount of water used for crystallization may be at least 2 times of the solvent employed. Preferable amount of water needed may be four times of the solvent used.

DETAILED DESCRIPTION OF THE INVENTION

20 Among the various processes known in the art, carbethoxylation of loratadine appears to be more relevant. The processes disclosed in the Hungarian Patent Number 194 864, European Patent No.0152 897 and PCT application NO.WO 8503707, teach boiling/refluxing loratadine with Aqueous ethanol and KOH for 24 hrs., which results in the production crude form of DCL with about 70% yield. US Patent No. 5,595,997 advocates saponification of Loratadine using NaOH and absolute EtOH for 4 days to produce DCL as
25 pale tan solid. US Patent No. 4,659,716;4,826,853 also advise refluxing Loratadine with Aqueous EtOH and KOH for about 60 hrs to produce DCL.

The literature does not report use of neat alcohol in combination with alkali metal hydroxide to produce stable DCL from loratadine.

30 In the process according to this invention, loratadine is reacted with neat alcohol in presence of an inorganic base to produce DCL.

According to a preferred realization loratadine is heated at a temperature between 60°C to 100°C or at respective refluxing temperature.

Further, it is observed that the loratadine when heated with neat MeOH and NaOH for about 1 to 6 hrs produces DCL that can be isolated easily by adding excess of water in pure crystalline form with high yield. The product obtained does not develop any colour on storage and meets all ICH requirements, GMP requirements & health registration requirements. Thus the process of the present invention is easy to operate, environment friendly economic and useful for commercial production.

The starting material of the compound of the invention is loratadine (8-chloro-6,11-dihydro-11-(1-ethoxycarbonyl-4-piperidilydene(-5H-benzo[5,6]cyclohepta [1,2b]pyridine). The synthesis of loratadine is described in detail in the US Patent no. 4,282,233.

During the course of the development of the process of the present invention, DCL was found to develop colour on storing for about > 4 months when KOH is used as inorganic base. Further additional efforts such as purification with MeOH-isopropyl ether, are needed to get the compound of required quality.

It has been observed that the increase is directly proportional to reaction time and decrease in the base results in increase in the reaction time.

It has also been noticed that inorganic base such as Lithium compounds and carbonates of alkali metals do not work. Similarly polyols fail to produce DCL.

The process of the present invention is further illustrated by the following examples. However, it should not limit the scope of the invention.

EXAMPLE - 1

A mixture of 8-chloro-6, 11-dihydro-11- (1-ethoxycarbonyl-4-piperidilydene) - 5H- benzo [5,6] cyclohepta [1,2-b] pyridine (100 gm, 0.2612 mole), sodium hydroxide (110 gm, 2.75 mole) in methanol (400 ml, 9.89 mole) was refluxed for 2 hrs at 82o to 95oC. After completion of reaction, 1000 ml of water is added to obtain crystals of 8-chloro-6, 11-dihydro-11-(4-piperidilydene) - 5H-benzo [5,6] cyclohepta [1,2-b] pyridine, which was filtered at 25o-30oC, washed with plenty of water to remove salts, dried at 50-55oC. The isolated yield was 76 gm., with a purity of 99.8% (OAB, HPLC) and an absorbance of 0.043 at 430 nm. giving a yield of 93.6%

The structure of the compound was confirmed by comparison of its I.R., NMR and Mass Spectra of reference standards. The quality results are shown in Table – 3.

EXAMPLE – 2

5

The reaction is carried out as described in Example 1, but the amount of methanol used was 600ml (14.83 mole) instead of 400ml. The reaction was completed in 12 hrs. The isolated yield of 8-chloro-6, 11-dihydro-11-(4-piperidilydene) – 5H-benzo [5,6] cyclohepta (1,2-b) pyridine was 72 gm with a purity of 99.6% (OAB, HPLC) and an absorbance of 0.083 at 430 nm. giving a yield of 88.7%

10

EXAMPLE – 3

The reaction was carried out as described in Example 1, but the amount of sodium hydroxide used was 92 gm (2.3 mole) instead of 110 gm. The reaction is completed in 8 hrs. The isolated yield of 8-chloro-6, 11-dihydro-11-(4-piperidilydene) – 5H-benzo [5,6] cyclohepta (1,2-b) pyridine was 71 gm with a purity of 99.7% (OAB, HPLC) and an absorbance of 0.09 at 430 nm. giving a yield of 87.5%

15

20

EXAMPLE – 4

The reaction was carried out as described in Example 1, but the ethanol (400 ml, 6.83 mole) was used instead of methanol (400ml). The reaction is completed in 5 hrs. The isolated yield of 8-chloro-6, 11-dihydro-11-(4-piperidilydene) – 5H-benzo [5,6] cyclohepta (1,2-b) pyridine was 72 gm with a purity of 99.5% (OAB, HPLC) and an absorbance of 0.6 at 430 nm. giving a yield of 88.7% Further purification with methanol- isopropyl ether results in 92% yield, and 0.1 absorbance.

25

30

EXAMPLE – 5

The reaction was carried out as described in Example 1, but the isopropanol (400ml, 5.23 mole) and potassium hydroxide (160gm, 2.857 mole) were used instead of methanol (400ml) and sodium hydroxide (110gm). The reaction is completed in 4 hrs. The isolated

yield of 8-chloro-6, 11-dihydro-11-(4-piperidilydene) – 5H-benzo [5,6] cyclohepta (1,2-b) pyridine was 75 gm with a purity of 99.6% (OAB, HPLC) and an absorbance of 0.27 at 430 nm. giving a yield of 92.4% further purification as in example 4 results in the compound with absorbance of 0.07. The yield has increased to 83.8%

5

EXAMPLE – 6

The reaction was carried out as described in Example 5, but the amount of isopropanol and potassium hydroxide used was one litre (21.23 mole) and 100gm (1.786 mole) respectively instead of 400ml and 160 gm. The reaction is completed in 50 hrs. The isolated yield of 8-chloro-6, 11-dihydro-11-(4-piperidilydene) – 5H-benzo [5,6] cyclohepta (1,2-b) pyridine was 76 gm with a purity of 99.7% (OAB, HPLC) and an absorbance of 0.2 at 430 nm. giving a yield of 93.62% On purification yield was 82.5 and colour absorbance was 0.06.

15

EXAMPLE – 7

The reaction was carried out as described in Example 1, but the n-propanol (400ml, 5.36 mole) was used instead of methanol (400ml). The reaction is completed in 4 hrs. The isolated yield of 8-chloro-6, 11-dihydro-11-(4-piperidilydene) – 5H-benzo [5,6] cyclohepta (1,2-b) pyridine was 72 gm with a purity of 99.5% (OAB, HPLC) giving a yield of 88.7%. Further purification in methanol- isopropyl ether provides the yield of 64 gm (78.8 %) with an absorbance of 0.09 (430 nm).

20

EXAMPLE – 8

25

The reaction was carried out as described in Example 1, but the n-propanol (400ml, 5.36 mole) and potassium hydroxide (160gm, 2.857 mole) were used instead of methanol (400ml) and sodium hydroxide (110gm). The reaction is completed in one hrs. The isolated yield of 8-chloro-6, 11-dihydro-11-(4-piperidilydene) – 5H-benzo [5,6] cyclohepta (1,2-b) pyridine was 74 gm with a purity of 99.47% giving a yield of 91.2%. Further purification in methanol- isopropyl ether was achieved to get a yield of 66gm (81.3%) with an absorbance of 0.08 (430 nm).

30

EXAMPLE - 9

The reaction was carried out as described in Example 1, but the n-butanol (400ml, 4.37 mole) was used instead of methanol (400ml). The reaction is completed in 3 hrs. The isolated yield of 8-chloro-6, 11-dihydro-11-(4-piperidilydene) - 5H-benzo [5,6] cyclohepta (1,2-b) pyridine was 72 gm with a purity of 99.6% (OAB, HPLC) giving a yield of 88.7%. This was further purified to get an absorbance of 0.08 and yield of 65 gm (80.1%).

EXAMPLE - 10

The reaction was carried out as described in Example 1, but the n-butanol (400ml, 4.37 mole) and potassium hydroxide (160gm, 2.857 mole) were used instead of methanol (400ml) and sodium hydroxide (110gm). The reaction is completed in one hrs. The isolated yield of 8-chloro-6, 11-dihydro-11-(4-piperidilydene) - 5H-benzo [5,6] cyclohepta (1,2-b) pyridine was 74 gm which is further purified in methanol- isopropyl to get product with a purity of 99.7% (OAB, HPLC) and an absorbance of 0.08 (430 nm) giving a yield of 82.5%.

EXAMPLE - 11

The reaction was carried out as described in Example 1, but the benzyl alcohol (400ml, 3.87 mole) was used instead of methanol (400ml). The reaction is completed in 3 hrs. The isolated yield of 8-chloro-6, 11-dihydro-11-(4-piperidilydene) - 5H-benzo [5,6] cyclohepta (1,2-b) pyridine was 73 gm which was further purified in methanol- isopropyl ether to get purity 99.76% (OAB, HPLC) and an absorbance of 0.08 (430 nm) giving a yield of 80.1%.

EXAMPLE - 12

The reaction was carried out as described in Example 1, but the benzyl alcohol (400ml, 3.87 mole) and potassium hydroxide (160gm, 2.857 mole) were used instead of methanol (400ml) and sodium hydroxide (110gm). The reaction is completed in 1.5 hrs. The isolated yield of 8-chloro-6, 11-dihydro-11-(4-piperidilydene) - 5H-benzo [5,6] cyclohepta (1,2-b) pyridine was 74 gm as base. This was crystallized in methanol- isopropyl ether to get a purity of 99.6% (OAB, HPLC) and an absorbance of 0.09 (430 nm) giving a yield of 66gm (81.3%).

Table 1 & Table 2 are hereby incorporated to indicate reaction time and quality results of preparation of DCL and proportion of various ingredients used for the preparation of DCL, respectively.

Moo2/02

Table – 1 Reaction time and quality result of preparation of 8-chloro-6, 11-dihydro-11- (-4-piperidylidene) – 5H- benzo [5,6] cyclohepta [1,2-b] pyridine (Formula –1).

S. No.	Lora t- dine (gm)	Neat Solvents (ml)								Base (gm)		Purity (HPLC) (%)	Yield (%)	Colour Absorbance at 430 nm	Reac tion Time (hrs)	Remarks
		MeO H	EtOH	n-Pr.	n- But.	I-Pr.	Benz yl Alco hol	DM SO	NaoH	KoH						
01.	100	400	-	-	-	-	-	-	110	-	99.8	93.6	0.043	2	NP	
02.	100	600	-	-	-	-	-	-	110	-	99.6	88.7	0.083	12	"	
03.	100	400	-	-	-	-	-	-	92	-	99.7	87.5	0.09	8	"	
04.	100	400	-	-	-	-	-	-	-	160	99.7	92.0	0.10	3	"	
05.	100	-	400	-	-	-	-	-	110	-	99.5	77.6	0.10	5	P	
06.	100	-	400	-	-	-	-	-	-	160	99.6	78.0	0.12	2	"	
07.	100	-	-	400	-	-	-	-	110	-	99.5	78.8	0.09	4	"	
08.	100	-	-	400	-	-	-	-	-	160	99.4	81.3	0.08	1	"	
09.	100	-	-	-	400	-	-	-	110	-	99.6	80.1	0.08	3	"	
10.	100	-	-	-	400	-	-	-	-	160	99.7	82.5	0.08	1	"	
11.	100	-	-	-	-	400	-	-	-	160	99.7	83.8	0.07	4	"	
12.	100	-	-	-	-	300	-	-	-	75	99.6	84.2	0.07	21	"	
13.	100	-	-	-	-	500	-	-	-	100	99.5	85.0	0.09	20	"	
14.	100	-	-	-	-	1000	-	-	-	100	99.7	82.5	0.06	50	"	
15.	100	-	-	-	-	-	400	-	110	-	99.7	80.1	0.08	3	"	
16.	100	-	-	-	-	-	400	-	-	160	99.6	81.3	0.09	1.5	"	
17.	100	-	-	-	-	-	-	400	110	-	99.4	80.3	0.12	3	"	
18.	100	-	-	-	-	-	-	400	-	160	99.5	80.1	0.15	3	"	
19.	100	300	-	-	-	-	-	-	-	75	99.6	92.1	0.09	30	NP	
20.	100	300	-	-	-	-	-	-	-	100	99.7	92.8	0.08	20	"	

NP- No Purification Required
P- Purification Required

Moo2/02

Table - 2 Reaction for the preparation of 8-chloro-6, 11-dihydro-11- (4-piperidylidene) - 5H- benzo [5,6] cyclohepta [1,2-b] pyridine (Formula-1) were failed in the following combination of Solvents and Base.

S. No.	Lorata-dine (gm)	Neat Solvents (ml)				Base (gm)				Reaction
		MeOH	Ethylon Glycol	1,2,3-Propane Triol	DMF	NaoH	KoH	Na ₂ CO ₃	K ₂ CO ₃	
01.	100	400	-	-	-	-	-	124	-	No reaction
02.	100	400	-	-	-	-	-	-	190	"
03.	100	-	-	-	400	110	-	-	-	"
04.	100	-	-	-	400	-	160	-	-	"
05.	100	-	400	-	-	110	-	-	-	"
06.	100	-	400	-	-	-	160	-	-	"
07.	100	-	-	400	-	110	-	-	-	"
08.	100	-	-	400	-	-	160	-	-	"

Table - 3 Quality Result of 8-chloro-6, 11-dihydro-11- (4-piperidylidene) - 5H- benzo [5,6] cyclohepta [1,2-b] pyridine described in Example - 1 (three batches)

S. NO.	TESTS	EXAMPLE - 1		
		Ia	Ib	Ic
01.	Water (% w/w)	0.25	0.20	0.27
02.	Colour Absorbance (A) at 430 nm	0.048	0.050	0.043
03.	Melting Range (°C)	152-155	152-155	152-155
04.	Assay (OAB, HPLC) % w/w	99.72	99.78	99.85
05.	Impurities (% w/w) total	0.06	0.06	0.06
06.	Sulphated Ash (% w/w)	0.03	0.05	0.05
07.	Residual Solvents (Methanol) ppm	1167	762	1933

We claim:

1. An improved process for the production of Desloratadine which comprises, reacting
loratadine with neat alcohol in presence of inorganic base, and isolating the title
5 compound in crystalline form by conventional methods on addition of excess water.
2. An improved process as claimed in claim 1 wherein the alcohol used is alkanols of
1 to 10 carbon atoms
3. An improved process as claimed in claim 2 wherein the alkanols of 1 to 10 carbon
atoms used are methanol, ethanol, propanol, isopropanol, tert. butyl alcohol,
10 pentanol, hexanol, cycloalkanols such as cyclohexanol; aromatic alcohols such as
benzyl alcohol.
4. An improved process as claimed in claim 1 wherein the alcohol used is a C₁-C₄
alkanol, preferably methanol.
5. An improved process as claimed in claim 1 wherein the amount of alcohol used
15 vary between 1 and 10 (w/v) equivalents calculated on the starting compound
loratadine.
6. An improved process as claimed in claim 1 wherein the amount of alcohol used is
2-6 (w/v) equivalents, preferably be 4 equivalents.
7. An improved process as claimed in claim 1 wherein the inorganic base used is
20 alkali metal hydroxides.
8. An improved process as claimed in claim 7 wherein the alkali metal hydroxide such
as sodium hydroxide, potassium hydroxide are used.
9. An improved process as claimed in claim 7 wherein the alkali metal hydroxides
used is sodium hydroxide.
- 25 10. An improved process as claimed in claim 1 wherein the amount of inorganic base
used vary between 0.5 and 1.6 (w/w) equivalents calculated on the starting
compound loratadine
11. An improved process as claimed in claim 1 wherein 1-1.6 (w/w) equivalents of base
is used
- 30 12. An improved process as claimed in claim 1 wherein the base used is 1.1 (w/w)
equivalents.
13. An improved process as claimed in claim 1 wherein the reaction is carried out at a
temperature between 60° and 100° C or at respective refluxing temperature,
preferably between 80° and 95° C more preferably between 85 to 90°C.

14. An improved process as claimed in claim 1 wherein the amount of water added is 2 to 4 times of the solvent employed.
15. An improved process where in the isolation is effected by filtration.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/IN 02/00193

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>WO 95 10514 A (SCHERING CORP) 20 April 1995 (1995-04-20) * 8-Chloro-11-(4-Piperidylidene)-6,11-Dihydro-5H-Benzo[5,6]Cyclohepta[1,2-b]Pyridine *</p> <p>page 52</p> <p style="text-align: center;">-/-</p>	1-15

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

6 March 2003

Date of mailing of the international search report

17/03/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3018

Authorized officer

Baston, E

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IN 02/00193

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>IWASAKI N ET AL: "AMPHOTERIC DRUGS. II. SYNTHESIS AND ANTIALLERGIC ACTIVITY OF (4-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLIDENE)P IPERIDINO)ALKANOIC ACID DERIVATIVES AND RELATED COMPOUNDS"</p> <p>CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN. TOKYO, JP,</p> <p>vol. 42, no. II, November 1999 (1999-11), pages 2285-2290, XP000919401</p> <p>ISSN: 0009-2363</p> <p>* page 2289, experimental section, preparation of compound 4a *</p>	1-15
Y	<p>CID M M ET AL: "NEW SYNTHESIS OF CYPROHEPTADINE AND RELATED COMPOUNDS USING LOW VALENT"</p> <p>TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL,</p> <p>vol. 44, no. 19, 1988, pages 6197-6200, XP002029414</p> <p>ISSN: 0040-4020</p> <p>page 6200; example 3H</p>	1-15
A	<p>EP 0 270 818 A (SCHERING CORP)</p> <p>15 June 1988 (1988-06-15)</p> <p>page 76</p>	1-15
A	<p>WO 96 31478 A (SCHERING CORP ; PHARMACOEPIA INC (US)) 10 October 1996 (1996-10-10)</p> <p>cited in the application</p> <p>* Page 26, line 10-15 *</p>	1-15

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/1994/00193

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9510514 A	20-04-1995	AT 210653 T	15-12-2001
		AU 698960 B2	12-11-1998
		AU 7970294 A	04-05-1995
		CA 2173963 A1	20-04-1995
		DE 69429440 D1	24-01-2002
		DE 69429440 T2	08-08-2002
		EP 0723539 A1	31-07-1996
		ES 2164717 T3	01-03-2002
		HU 76057 A2	30-06-1997
		JP 2875392 B2	31-03-1999
		JP 8510445 T	05-11-1996
		NZ 275646 A	26-02-1998
		SG 43768 A1	14-11-1997
		WO 9510514 A1	20-04-1995
		US 5661152 A	26-08-1997
		ZA 9407969 A	12-07-1996
EP 0270818 A	15-06-1988	US 4826853 A	02-05-1989
		AT 116310 T	15-01-1995
		AU 635400 B2	18-03-1993
		AU 7285991 A	30-05-1991
		AU 604285 B2	13-12-1990
		AU 8336287 A	25-05-1988
		CA 1305147 A1	14-07-1992
		CA 1321589 A2	24-08-1993
		CS 9104143 A3	16-09-1992
		DE 3750929 D1	09-02-1995
		DE 3750929 T2	01-06-1995
		DK 73193 A	21-06-1993
		DK 354688 A	28-06-1988
		EP 0270818 A1	15-06-1988
		EP 0330673 A1	06-09-1989
		EP 0685476 A1	06-12-1995
		ES 2068179 T3	16-04-1995
		FI 891806 A ,B,	17-04-1989
		HK 186396 A	11-10-1996
		IE 65174 B1	04-10-1995
		JP 6078316 B	05-10-1994
		JP 2500910 T	29-03-1990
		KR 9302489 B1	02-04-1993
		NO 882907 A ,B,	29-06-1988
		NZ 222347 A	27-03-1990
		OA 9546 A	31-01-1993
		PH 26184 A	18-03-1992
		SG 44597 A1	19-12-1997
		WO 8803138 A1	05-05-1988
		US 5089496 A	18-02-1992
		US 5665726 A	09-09-1997
		US 5438062 A	01-08-1995
		ZA 8708128 A	29-04-1988
WO 9631478 A	10-10-1996	AU 719990 B2	18-05-2000
		AU 5527996 A	23-10-1996
		BR 9604787 A	07-07-1998
		CA 2217499 A1	10-10-1996
		CZ 9703165 A3	18-03-1998
		EP 0819121 A1	21-01-1998
		HU 9800456 A2	28-06-1999

INTERNATIONAL SEARCH REPORT

International publication No
PCT/IN 02/00193

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9631478	A	IL 117798 A	25-11-2001
		JP 3038017 B2	08-05-2000
		JP 10511981 T	17-11-1998
		NO 974610 A	08-12-1997
		NZ 306665 A	28-01-2000
		PL 322689 A1	16-02-1998
		SK 135597 A3	08-07-1998
		TW 462968 B	11-11-2001
		WO 9631478 A1	10-10-1996
		US 6214827 B1	10-04-2001
		US 5801175 A	01-09-1998